Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025

Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV,OTC:CVALF; OTCQX: CVALF), an advanced medical technologies company improving lives through innovative wound care, vascular access, and surgical solutions, is pleased to announce its participation at the Planet MicroCap Showcase: TORONTO 2025, in partnership with MicroCapClub.

Brent Ashton, Covalon's Chief Executive Officer, will participate in a fireside chat with Mathieu Martin, Portfolio Manager at Rivemont MicroCap Fund, at the Arcadian Loft in downtown Toronto on Wednesday, October 22, 2025, at 12:30 p.m. (ET).

This engaging session will spotlight why Covalon is positioned squarely in the "sweet spot" of the microcap landscape — a profitable, debt-free, cash-rich, undervalued healthcare company that remains largely undiscovered by investors.

Key highlights Brent will discuss with Mathieu include:

  • Why microcap companies like Covalon have the ability to outperform major medical device companies
  • Recent breakthrough clinical and health economic evidence that validates the company's products, and how this will drive value for the Company
  • Covalon's strong cash and debt-free position and how the Company plans to use this to accelerate shareholder value
  • How Covalon is leveraging these catalysts to drive future business success
  • The Company's insights into US macro-level volatility and how Covalon is turning potential challenges into opportunities for Covalon products

"I'm thrilled to be involved in the Planet MicroCap Showcase: TORONTO 2025 event," said Brent Ashton, CEO of Covalon. "Covalon's participation at the Vancouver 2024 and Las Vegas 2025 events were very productive and gave the Company a great opportunity to engage with numerous existing and prospective shareholders. The upcoming Toronto event offers another exciting venue to connect directly with investors who are interested in learning more about Covalon's value and growth potential.

Partnering with long-time Covalon shareholder and seasoned microcap portfolio manager Mathieu Martin from the Rivemont MicroCap Fund brings a unique perspective to our participation — a dialogue that will blend the company's vision with an institutional investor's insights."

Interested investors are invited to register to attend at https://www.meetmax.com/sched/event_123229/conference_register.html or can watch the presentation online at https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/Vmx3XEW4QrWwEN3WCYsUV4 .

Those interested in learning more about Covalon's solutions may visit www.covalon.com or follow Covalon on LinkedIn , Facebook , Instagram , or X .

About Covalon

Covalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca , any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

To learn more about Covalon, please contact:

Brent Ashton, Chief Executive Officer, Covalon Technologies Ltd.
Email: investors@covalon.com
Phone: 1.877.711.6055
Website: https://covalon.com/

News Provided by Business Wire via QuoteMedia

COV:CA
The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News